§ Claim under review · Health
"Scientists at the University of New Mexico developed a vaccine that targets the tau protein, which in animal trials (mice and rhesus macaques) dramatically reduced tau plaques and is now moving toward human clinical trials as a potential treatment for Alzheimer's disease." (Instagram, @elixirofscience)
Verdict
Mostly accurate
Confidence
HighSummary
This one is largely real. Scientists at the University of New Mexico did develop an experimental vaccine that targets a harmful form of the tau protein, and they published the results in a peer-reviewed Alzheimer's Association journal in 2025. In genetically modified mice, the vaccine reduced tau buildup and brain shrinkage and improved memory and motor performance. A human Phase 1 trial is genuinely funded with a $1 million grant and was being prepared to enroll patients. Two things in the post are off. The monkeys in the study were only tested for safety and antibody response, not for clearing tau, so the claim that it reduced tau in monkeys overstates what was shown. And tau forms tangles inside brain cells, not plaques. Important context the post leaves out: several earlier anti-tau treatments passed safety testing in humans and then failed to slow memory loss, and the upcoming trial is designed to test safety, not whether the vaccine works. Also worth noting, the post uses this research as a lead-in to promote supplements that have nothing to do with the study.
The readings
key figures from the evidenceAlzheimer's Association Part the Cloud grant for the trial
planned duration of the Phase 1a/1b human trial
Why this verdict
Evidence
The cited study is real, correctly titled (the post drops one word, "of"), and was published in the Alzheimer's Association's peer-reviewed journal in March 2025. The corresponding author is Kiran Bhaskar of the University of New Mexico, with the VLP platform developed by UNM colleagues Bryce Chackerian and David Peabody, and macaque work done with the California National Primate Research Center at UC Davis.
What the paper reports: two vaccine doses of pT181-Qß, without adjuvants, elicited robust antibody responses in two mouse models of tauopathy (PS19 and hTau) and in rhesus macaques. In the mouse models, vaccination reduced AT180+ hyperphosphorylated, Sarkosyl-insoluble, Gallyas-silver-positive tau, inflammasomes and neuroinflammation, and improved recognition memory and motor function without inducing adverse T-cell activation.
Anti-pT181 antibodies were reactive to pathological tau in human Alzheimer's brains, engaged pT181+ tau in human brain lysates, and were central nervous system bioavailable. The authors' own conclusion is measured: the results suggest translational utility of pT181-Qß against tauopathies.
Critically, the pathology and behavior benefits are reported for mice only. The paper's highlights state that pT181-Qß vaccination reduces pathological tau and brain atrophy and improves memory and motor function in PS19 and hTau mice. In the macaques, six adult rhesus macaques were vaccinated, three with the experimental vaccine and three with a control, and the vaccinated monkeys developed high levels of anti-pT181 antibodies that were also detected in cerebrospinal fluid, suggesting the antibodies crossed into the brain. Macaques are not a tauopathy disease model, so no plaque or tangle clearance was demonstrated in them.
On the human trial claim: UNM received early-phase funding to launch a clinical trial for the vaccine, which has been exclusively licensed to TheraVac Biologics, Inc. The Phase 1a/1b trial, supported in part by a $1 million grant from the Alzheimer's Association's Part the Cloud initiative, will assess safety, tolerability, and immunogenicity.
The trial will be conducted at the UNM Center for Memory & Aging and was expected to start enrolling patients in early 2026.
It is planned as a double-blind study lasting about 12 months, with half of subjects receiving active vaccine and half placebo. Bhaskar himself framed the endpoints narrowly: the primary endpoint is safety and tolerability, and the second endpoint is immunogenicity, whether subjects can make antibodies to tau.
The UNM team also acknowledged the limits directly: animal models and test tube experiments are not sufficient to prove the vaccine will work in human subjects.
Findings
✓ What's accurate 8
- The University of New Mexico attribution is correct. Bhaskar, Chackerian, Peabody and colleagues developed pT181-Qß at UNM.
- The cited study title is real and essentially verbatim, published in a legitimate peer-reviewed Alzheimer's journal in 2025.
- The vaccine does target phosphorylated tau, specifically at threonine 181, using a Qβ bacteriophage virus-like particle platform.
- Both mice and rhesus macaques were tested.
- Tau pathology was substantially reduced in the mouse models, alongside less neuroinflammation, less brain atrophy, and better memory and motor performance.
- Antibodies reached the cerebrospinal fluid in macaques and bound human Alzheimer's tau in lab tests.
- A Phase 1 human trial is genuinely funded, licensed, and being prepared. This part of the claim is if anything understated, since the funding was secured in July 2025.
- The description of the mechanism in the caption, an active immunotherapy prompting the body to make its own antibodies rather than treating symptoms, is accurate.
≈ What's misleading 6
- **Species conflation**: The claim states the vaccine "in animal trials (mice and rhesus macaques) dramatically reduced tau plaques." Pathology reduction was demonstrated only in mice. The macaque arm measured antibody response and safety. Macaques do not spontaneously develop Alzheimer's tau pathology, so nothing was cleared in them. Note that the paper's own title ("reduces disease severity in mice and rhesus macaques") invites this misreading, so the post is repeating an overreach that originates with the authors.
- **Terminology error**: "Tau plaques" is not a thing. Tau forms neurofibrillary tangles inside neurons; plaques are extracellular amyloid beta deposits. The caption itself correctly describes tau as accumulating inside neurons and then contradicts that by saying "plaques." Minor scientifically, but it blurs the distinction between this vaccine and the amyloid drugs it is being contrasted with.
- **Exaggeration**: "Dramatically," "beyond expectations," "major breakthrough," and "one of the most significant medical breakthroughs in recent decades" are the post's words, not the paper's. The authors wrote only that results "suggest the translational utility" of the vaccine.
- **Temporal overreach**: Framing a preclinical result plus a not-yet-started Phase 1 safety trial as meaning Alzheimer's prevention is "no longer out of reach." A Phase 1a/1b trial measures safety and antibody production. It is not designed to show the disease is halted or prevented.
- **Omitted context**: The post does not mention that multiple prior tau immunotherapies cleared safety hurdles and then failed to slow cognitive decline in humans. Nor does it mention the vaccine is licensed to a private company, TheraVac Biologics, which has a commercial interest.
- **Commercial bait-and-switch**: The post attaches a supplement affiliate pitch ("Which supplements are actually worth taking for preventing dementia... linked in my bio") to legitimate vaccine research. The study has no connection whatsoever to supplements. Using credible institutional science as the hook for an unrelated product funnel is the most misleading element of the post as a whole, even though it is not a false factual assertion about the study.
? What's uncertain 4
- Whether the Phase 1a/1b trial has actually opened enrollment or dosed a first participant. I found no trial registry entry, no NCT number, and no post-2025 status update for this vaccine.
- Whether FDA IND clearance has been granted. Reporting describes GMP manufacturing as a prerequisite, not a completed step.
- The exact magnitude of tau reduction in mice. The abstract and available coverage describe direction of effect, not effect sizes or confidence intervals. I did not retrieve the full figures and statistics.
- Whether any macaque brain tissue endpoints were assessed at all beyond antibody bioavailability.
Sources
3 of 6 linked to records**Maphis NM, Hulse J, et al. "Targeting of phosphorylated tau at threonine 181 by a Qβ virus-like particle vaccine is safe, highly immunogenic, and reduces disease severity in mice and rhesus macaques." Alzheimer's & Dementia, 2025;21:e70101**
**UNM Health Sciences Newsroom, "UNM Researchers Receive Funding to Launch Clinical Trial of a New Alzheimer's Vaccine," July 14, 2025**
**UNM Rainforest Innovations, "Phase 1 Clinical Trial Set to Begin for UNM-Developed Alzheimer's Vaccine," July 21, 2025**
**Alzheimer's Association Part the Cloud grant announcement (PMC12260113)**
**Maphis et al., npj Vaccines 2019 (PMC6547647)**
Secondary coverage: Neuroscience News, Medical Xpress, PsyPost, The Medicine Maker, News-Medical, Open Access Government